n/a
Abstract Title:

Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial.

Abstract Source:

Complement Ther Med. 2020 Aug ;52:102494. Epub 2020 Jun 23. PMID: 32951743

Abstract Author(s):

Muhammad Amjad Pervez, Dilshad Ahmed Khan, Atiq Ur Rehman Slehria, Aamir Ijaz

Article Affiliation:

Muhammad Amjad Pervez

Abstract:

OBJECTIVE: The aim of this study was to examine the effects of delta-tocotrienol (δ-tocotrienol) supplementation on biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease (NAFLD).

DESIGN: The study design was a two-group, randomized, double-blind, placebo-controlled trial. The patients with NAFLD were randomly assigned to receiveδ-tocotrienol 300 mg twice daily or placebo for 24 weeks.

ENDPOINTS: The primary endpoints were change from baseline in fatty liver index (FLI) and homeostasis model of insulin resistance (HOMA-IR) after 24 weeks. Secondary endpoints included change from baseline in high sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA), alanine transaminase (ALT), aspartate transaminase (AST) and grading of hepatic steatosis on ultrasound. Between-group differences were tested for significance using ANCOVA. Mean differences (MD) with 95 % CIs are reported.

RESULTS: A total of 71 patients (tocotrienol=35, placebo=36) were randomized and included in the intention to treat analysis. Compared with placebo,δ-tocotrienol significantly reduced (MD [95 % CI]) FLI (-8.52 [-10.7, -6.3]; p<0.001); HOMA-IR (-0.37 [-0.53, -0.21]; p<0.001), hs-CRP (-0.61[-0.81, -0.42]; p<0.001), MDA (-0.91 [-1.20, -0.63]; p<0.001), ALT (-8.86 [-11.5, -6.2]; p<0.001) and AST (-6.6 [-10.0, -3.08]; p<0.001). Hepatic steatosis was also reduced by a significantly greater extent with tocotrienol than with placebo (p =0.047). No adverse events were reported.

CONCLUSION: δ-tocotrienol effectively improved biochemical markers of hepatocellular injury and steatosis in patients with NAFLD. δ-tocotrienol supplementation might be considered as a therapeutic option in the management of patients with NAFLD.

TRIAL REGISTRATION: Sri Lankan Clinical Trials Registry (SLCTR/2015/023, 2015-10-03).

Study Type : Human Study

Print Options


Key Research Topics

Sayer Ji
Founder of GreenMedInfo.com

Subscribe to our informative Newsletter & get Nature's Evidence-Based Pharmacy

Our newsletter serves 500,000 with essential news, research & healthy tips, daily.

Download Now

500+ pages of Natural Medicine Alternatives and Information.

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2021 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.